SB 239063
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD[1][2].
Product Specifications
CAS Number
[193551-21-2]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/SB-239063.html
Purity
99.49
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
COC1=NC=CC(C2=C(N=CN2[C@H]3CC[C@H](O)CC3)C4=CC=C(F)C=C4)=N1
Molecular Formula
C20H21FN4O2
Molecular Weight
368.40
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
SFTPB, ID (SFTPB, SFTP3, Pulmonary surfactant-associated protein B, 18kD pulmonary-surfactant protein, 6kD protein, Pulmonary surfactant-associated proteolipid SPL(Phe)) (FITC)
SFTPB, ID (SFTPB, SFTP3, Pulmonary surfactant-associated protein B, 18kD pulmonary-surfactant protein, 6kD protein, Pulmonary surfactant-associated proteolipid SPL(Phe)) (FITC)
